Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 1225

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Prof Ola Landgren speaks to ecancer at the 2019 International Myeloma Workshop meeting in Boston on a phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma.

He explains that the study was designed to decipher which was the safest dose, with the weekly dosing of 56mg/m2 once a week deemed the safest and most efficacious dose.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation